Blood sample

Innovative blood test could revolutionise cancer care

The Royal Marsden NHS Foundation Trust has launched an innovative trial that could detect breast cancer relapses months and even years in advance.

As part of this international undertaking, researchers will first recruit oestrogen receptor (ER) positive breast cancer patients to the trial; the patients will then have a blood test every three months for as many as three years, so the researchers can determine whether a patient’s cancer is returning.

The blood test works by monitoring the levels of circulating tumour DNA (ctDNA) in a given blood sample. The test can detect even the smallest amounts of ctDNA in a sample and can therefore alert researchers to whether a patient is having a molecular relapse – i.e. cancer is returning and patient is going to relapse.

Evaluating patients this way enables clinicians to catch the cancer at the earliest stage possible, with some ctDNA having previously identified relapsing patients months and even years before it would’ve been noticeable on a scan.

Principal investigator of the TRAK-ER trial, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Head of the Ralph Lauren Centre for Breast Cancer Research at The Royal Marsden, Professor Nicholas Turner, said: “The risk of relapse for ER positive breast cancer patients is spread out over many years after initial treatment, which is one of the reasons why scans aren't effective in trying to pick it up.

“Blood tests could become the standard way of following up with this group of patients, and if the trial produces encouraging results, this could revolutionise how we treat ER positive breast cancer patients in the future and hopefully save more lives.”

If a patient is found to have ctDNA in their bloodstream but there isn’t any observable abnormalities on a scan, they will go down one of two routes.

Patients will either be given palbociclib and fulvestrant or they will given an option of continuing the hormone treatment they are currently on or making a change.

This will allow researchers to assess the efficacy of treating patients with palbociclib and fulvestrant, compared to just standard hormone therapies.

National Health Executive, Nov/Dec, Cover

NHE Nov/Dec 22

How active travel can help staff save money, improve wellbeing and help meet net zero targets

This issue highlights the latest topics within the health sector, from the NHS outlining its net zero strategy, Virtual hospitals, sustainable healthcare, How the NHS can achieve financial stability and more with articles featuring industry leaders such as Rory Deighton, Acute Network Director for NHS Confederation, Dr Tom Milligan, Clinical Lead for Diabetes in Humber and North Yorkshire, Misha Garcia, Value Programme Lead, NHS Property Services and many more.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all